JP5674211B2 - インダゾリル置換のジヒドロイソオキサゾロピリジンおよびその使用方法 - Google Patents

インダゾリル置換のジヒドロイソオキサゾロピリジンおよびその使用方法 Download PDF

Info

Publication number
JP5674211B2
JP5674211B2 JP2012518822A JP2012518822A JP5674211B2 JP 5674211 B2 JP5674211 B2 JP 5674211B2 JP 2012518822 A JP2012518822 A JP 2012518822A JP 2012518822 A JP2012518822 A JP 2012518822A JP 5674211 B2 JP5674211 B2 JP 5674211B2
Authority
JP
Japan
Prior art keywords
compound
formula
cancer
met
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012518822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532170A5 (enExample
JP2012532170A (ja
Inventor
マルティン・ミヒェルス
マルクス・フォルマン
アレクサンドロス・ヴァカロポウロス
カトヤ・ツィンマーマン
ニコレ・トイシュ
マリオ・ロベル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of JP2012532170A publication Critical patent/JP2012532170A/ja
Publication of JP2012532170A5 publication Critical patent/JP2012532170A5/ja
Application granted granted Critical
Publication of JP5674211B2 publication Critical patent/JP5674211B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2012518822A 2009-07-10 2010-07-07 インダゾリル置換のジヒドロイソオキサゾロピリジンおよびその使用方法 Expired - Fee Related JP5674211B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09008996 2009-07-10
EP09008996.2 2009-07-10
PCT/EP2010/004147 WO2011003604A1 (en) 2009-07-10 2010-07-07 Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2012532170A JP2012532170A (ja) 2012-12-13
JP2012532170A5 JP2012532170A5 (enExample) 2013-08-22
JP5674211B2 true JP5674211B2 (ja) 2015-02-25

Family

ID=42584913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012518822A Expired - Fee Related JP5674211B2 (ja) 2009-07-10 2010-07-07 インダゾリル置換のジヒドロイソオキサゾロピリジンおよびその使用方法

Country Status (7)

Country Link
US (1) US9073939B2 (enExample)
EP (1) EP2451817B1 (enExample)
JP (1) JP5674211B2 (enExample)
CN (1) CN102639537B (enExample)
CA (1) CA2767476A1 (enExample)
ES (1) ES2433228T3 (enExample)
WO (1) WO2011003604A1 (enExample)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635977A (en) 1969-11-03 1972-01-18 American Cyanamid Co Certain 6-trifluoromethylcytosines and thiocytosines their synthesis and their use in the synthesis of uracisls and thiouracil
JP2634640B2 (ja) 1988-07-29 1997-07-30 三共株式会社 縮環ジヒドロピリジン誘導体
US5274167A (en) 1989-01-26 1993-12-28 Bayer Aktiengesellschaft Polymeriable optically active (meth) acrylic acid derivatives
DK0379917T3 (da) 1989-01-26 1995-12-11 Bayer Ag Optisk aktive (meth)acrylsyre-drivater, deres fremstilling, deres polymerisation til optisk aktive polymere og disses anvendelse
DE19546136A1 (de) 1995-12-11 1997-06-12 Bayer Ag Chirale stationäre Phasen für die chromatographische Trennung von optischen Isomeren
WO2001066544A2 (en) 2000-03-03 2001-09-13 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
GB0220962D0 (en) * 2002-09-10 2002-10-23 Bayer Ag Heterocyclic derivatives
PT1638941E (pt) * 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
ES2394177T3 (es) * 2004-02-26 2013-01-23 Bayer Intellectual Property Gmbh 1,4-diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
US20070185152A1 (en) 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
WO2005084672A1 (de) 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
CA2589777A1 (en) 2004-12-13 2006-06-22 Irm Llc Compounds and compositions as modulators of steroidal receptors and calcium channel activities
CA2603676A1 (en) 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
WO2007053345A1 (en) * 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators
BRPI0710510A2 (pt) * 2006-04-19 2011-08-16 Novartis Ag compostos indazol e processos para inibição de cdc7
KR20090087919A (ko) 2006-12-14 2009-08-18 바이엘 쉐링 파마 악티엔게젤샤프트 단백질 키나제 억제제로서 유용한 디히드로피리딘 유도체
WO2009006580A1 (en) 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
JP5506788B2 (ja) * 2008-06-09 2014-05-28 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換４−（インダゾリル）−１，４−ジヒドロピリジン類およびそれらの使用方法
CA2727199C (en) * 2008-06-09 2016-11-22 Bayer Schering Pharma Aktiengesellschaft Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof
JP5753174B2 (ja) 2009-10-06 2015-07-22 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ フッ化２，６−ジアルキル−３，５−ジシアノ−４−（１ｈ−インダゾール−５−イル）−１，４−ジヒドロピリジン類およびそれらの使用方法

Also Published As

Publication number Publication date
ES2433228T3 (es) 2013-12-10
EP2451817A1 (en) 2012-05-16
US20120190709A1 (en) 2012-07-26
HK1174620A1 (zh) 2013-06-14
US9073939B2 (en) 2015-07-07
CN102639537B (zh) 2015-07-22
EP2451817B1 (en) 2013-09-04
CN102639537A (zh) 2012-08-15
CA2767476A1 (en) 2011-01-13
JP2012532170A (ja) 2012-12-13
WO2011003604A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
JP5506788B2 (ja) 置換４−（インダゾリル）−１，４−ジヒドロピリジン類およびそれらの使用方法
JP5638011B2 (ja) 二および三環式インダゾール置換１，４−ジヒドロピリジン誘導体およびそれらの使用
JP5480891B2 (ja) アネレート化４−（インダゾリル）−１，４−ジヒドロピリジン誘導体およびそれらの使用方法
KR20120091005A (ko) 플루오로-치환된 3,5-디시아노-4-(1ｈ-인다졸-5-일)-2,6-디메틸-1,4-디히드로피리딘 유도체 및 그의 사용 방법
JP5753174B2 (ja) フッ化２，６−ジアルキル−３，５−ジシアノ−４−（１ｈ−インダゾール−５−イル）−１，４−ジヒドロピリジン類およびそれらの使用方法
JP5674211B2 (ja) インダゾリル置換のジヒドロイソオキサゾロピリジンおよびその使用方法
JP5571800B2 (ja) フロピリジニル置換１，４−ジヒドロピリジン誘導体およびその使用方法
JP2012532170A5 (enExample)
JP5753182B2 (ja) フルオロ置換２−アリール−３，５−ジシアノ−４−インダゾリル−６−メチル−１，４−ジヒドロピリジンおよびその使用
HK1174620B (en) Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof
HK1166801B (en) Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
HK1176615A (en) Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20141215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141219

R150 Certificate of patent or registration of utility model

Ref document number: 5674211

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees